Merck sells eye business

Share this article:

First Merck sold its consumer business to Bayer. Now, it's also (almost) getting out of the eye-care business. The company announced Tuesday that it has sold part of the business to Santen Pharmaceutical.

The $600-million-plus-milestones deal includes rights to the eye products Cosop, Trusop and Timoptic in Japan and “key markets in Europe and Asia Pacific.” Merck said the sales for these products in these territories is around $400 million a year.

Merck will continue to sell these products in Latin America, Canada and Australia, but sold US rights to Akorn in 2013 and 2014.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.